Orthofix Medical’s (OFIX) Buy Rating Reiterated at Roth Mkm

Roth Mkm restated their buy rating on shares of Orthofix Medical (NASDAQ:OFIX) in a report published on Wednesday morning,Benzinga reports. Roth Mkm currently has a $22.00 target price on the medical device company’s stock.

A number of other research analysts have also recently commented on OFIX. Canaccord Genuity Group assumed coverage on shares of Orthofix Medical in a research note on Wednesday, January 22nd. They set a “buy” rating and a $24.00 price target for the company. StockNews.com upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, Stifel Nicolaus upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating and lifted their target price for the company from $18.00 to $24.00 in a research note on Friday, November 8th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $23.33.

Orthofix Medical Stock Up 1.0 %

Shares of OFIX opened at $17.38 on Wednesday. The stock has a market cap of $664.16 million, a price-to-earnings ratio of -5.55 and a beta of 1.10. The company has a quick ratio of 1.11, a current ratio of 2.39 and a debt-to-equity ratio of 0.25. Orthofix Medical has a 12 month low of $12.08 and a 12 month high of $20.73. The company has a 50-day moving average price of $17.93 and a two-hundred day moving average price of $17.35.

Insider Activity

In other news, CFO Julie Andrews sold 4,655 shares of Orthofix Medical stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $17.89, for a total value of $83,277.95. Following the completion of the transaction, the chief financial officer now owns 28,312 shares in the company, valued at approximately $506,501.68. The trade was a 14.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Massimo Calafiore sold 9,203 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $17.14, for a total transaction of $157,739.42. Following the completion of the sale, the chief executive officer now directly owns 124,151 shares of the company’s stock, valued at approximately $2,127,948.14. This represents a 6.90 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,442 shares of company stock worth $436,883. Insiders own 2.60% of the company’s stock.

Institutional Trading of Orthofix Medical

Institutional investors have recently bought and sold shares of the business. Lazard Asset Management LLC acquired a new stake in Orthofix Medical during the 4th quarter worth $45,000. R Squared Ltd acquired a new position in shares of Orthofix Medical in the 4th quarter valued at $50,000. KLP Kapitalforvaltning AS acquired a new position in shares of Orthofix Medical in the 4th quarter valued at $112,000. Tower Research Capital LLC TRC grew its holdings in shares of Orthofix Medical by 120.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,458 shares of the medical device company’s stock valued at $148,000 after buying an additional 4,627 shares during the period. Finally, State of Wyoming grew its holdings in shares of Orthofix Medical by 206.8% in the 4th quarter. State of Wyoming now owns 9,432 shares of the medical device company’s stock valued at $165,000 after buying an additional 6,358 shares during the period. Institutional investors and hedge funds own 89.76% of the company’s stock.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.